SHR2150

SHR2150 · Chinese PLA General Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SHR2150, covering 2020-10-19 to 2020-10-19. Get the full timeline:

Most recent: Clinical Trial Update: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors [Phase 1, Phase 2]

See pricing